In this insightful video presentation, Carl Zeiss Meditec AG, a leading medical technology company, reports on its performance during the first half of the fiscal year 2022/23. Despite challenging circumstances, such as the ongoing COVID-19 pandemic and strained global supply chains, the company achieved a remarkable 13.9% growth, generating around €974.5m in revenue. However, this robust revenue growth was offset by a decline in earnings before interest and taxes (EBIT), which dropped to €143.9m from the prior year’s €177.3m, primarily due to an unfavourable product mix and rising operational costs.
Notably, the Americas region recorded the most substantial growth, with revenue surging by an impressive 27.6%. The company’s strategic business units (SBUs) in Ophthalmology and Microsurgery contributed significantly to this growth. In contrast, the EBIT margin shrank to 14.8% from 20.7% in the previous year, largely due to the pandemic’s impact on the Chinese market, increased investment in research and development, higher procurement costs, and rising labour costs.
Despite the decrease in EBIT, the company’s CEO, Dr Markus Weber, expresses satisfaction with the company’s performance and reaffirms the company’s commitment to strategic investments in research and development, supply chain improvements, and shortening delivery times. Looking ahead, Carl Zeiss Meditec AG has consolidated its projections for the fiscal year 2022/23, expecting revenue to increase to around €2.1 billion, with the EBIT margin anticipated to be between 17-20%.
Reviews for Carl Zeiss Meditec AG Financial Results H1 2022 /23 | Achieving Double-Digit Growth with CEO and CFO